Jump to Main Contents
ncc en

Annual Report 2017

Department of Pediatric Surgical Oncology

Kazuaki Shimada, Tomoro Hishiki, Naonori Kawakubo

Introduction

 The Department of Pediatric Surgical Oncology was newly established in April 2016 to provide surgical treatment for pediatric cancers. Our team expertizes in surgeries for a wide variety of tumors including neuroblastomas, nephroblastomas, hepatoblastomas, Ewing sarcomas, rhabdomyosarcomas, osteosarcomas, germ cell tumors, and all other types of tumors arising in children and adolescents.

Our team and what we do

 The outpatient service of our department is open two days a week, Tuesday and Thursday, to treat newly diagnosed patients and to provide follow-up treatment for patients who received surgery. Weekly conferences are held with pediatric oncologists from the Department of Pediatric Oncology.

 We particularly expertize in performing surgical operations on infants and small children but also care for adolescent and young adult (AYA) patients in collaboration with expert surgeons of our adult team.

Research activities

 Our staff members play key roles in nationwide collaborative studies aimed to establish precision medicine for pediatric solid tumors using oncopanels designed to reveal targetable gene arrangements. We are also involved in translational research activities on immunotherapy for neuroblastoma and other solid tumors.

Clinical trials

 We have a leading role in clinical trials conducted by the Japan Children's Cancer Group (JCCG), with particular interest in neuroblastoma and hepatoblastoma.

Education

 We are accepting trainees and students worldwide and nationwide.

Future prospects

 Pediatric cancers that can be cured by surgery alone are very rare. Multidisciplinary treatment combined with surgery, chemotherapy, and radiotherapy is often needed to treat such disease. We collaborate with the Department of Pediatric Oncology and other related departments, and provide advanced treatment for pediatric patients.

List of papers published in January 2017 - March 2018

Journal

1. Hishiki T, Watanabe K, Ida K, Hoshino K, Iehara T, Aoki Y, Kazama T, Kihira K, Takama Y, Taguchi T, Fujimura J, Honda S, Matsumoto K, Mori M, Yano M, Yokoi A, Tanaka Y, Fuji H, Miyazaki O, Yoshimura K, Takimoto T, Hiyama E. The role of pulmonary metastasectomy for hepatoblastoma in children with metastasis at diagnosis: Results from the JPLT-2 study. J Pediatr Surg, 52:2051-2055, 2017

2. Meyers RL, Maibach R, Hiyama E, Haberle B, Krailo M, Rangaswami A, Aronson DC, Malogolowkin MH, Perilongo G, von Schweinitz D, Ansari M, Lopez-Terrada D, Tanaka Y, Alaggio R, Leuschner I, Hishiki T, Schmid I, Watanabe K, Yoshimura K, Feng Y, Rinaldi E, Saraceno D, Derosa M, Czauderna P. Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children's Hepatic tumors International Collaboration. Lancet Oncol, 18:122-131, 2017

3. Hishiki T, Mise N, Harada K, Ihara F, Takami M, Saito T, Terui K, Nakata M, Komatsu S, Yoshida H, Motohashi S. Frequency and proliferative response of circulating invariant natural killer T cells in pediatric patients with malignant solid tumors. Pediatr Surg Int, 34:169-176, 2018

4. Hishiki T, Mise N, Harada K, Ihara F, Takami M, Saito T, Terui K, Nakata M, Komatsu S, Yoshida H, Motohashi S. Invariant natural killer T infiltration in neuroblastoma with favorable outcome. Pediatr Surg Int, 34:195-201, 2018

5. Sakamoto S, Sasaki K, Uchida H, Kitajima T, Narumoto S, Hirata Y, Hishiki T, Fukuda A, Kasahara M. Ex vivo reduction of thickness in the left lateral section to tailor the graft size in infantile split deceased donor liver transplantation. Liver Transpl, 24:428-431, 2018